GAP43 and Alzheimer disease: Intriguingly, synaptophysin levels were reduced in the earliest stages of AD (mild AD) whilst there was no alteration in other presynaptic molecules such as synaptotagmin-1 or GAP-43, suggesting that early in disease progression there may be a selective reduction in synaptophysin (Masliah et al., 2001).